Profil
Giuseppina Caligiuri is the founder and currently holds the title of Director at Tridek-One Therapeutics SAS, which is founded in 2018.
Aktive Positionen von Giuseppina Caligiuri
| Unternehmen | Position | Beginn |
|---|---|---|
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Gründer | 01.06.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
